Dr. Gergel will have full responsibility for all of the company's R&Dactivities, including direct supervision of clinical research, pre-clinicalR&D, medical affairs, marketed product development support, regulatoryaffairs, project management and drug safety and surveillance.

From May 19, 2005 until March 31, 2008, Dr. Gergel had been Senior VicePresident of Scientific Affairs and President of the Forest ResearchInstitute of Forest Laboratories Inc., managing over 900 physicians,scientists and staff at the Research Institute. Prior to that, Dr. Gergelserved as Vice President and Chief Medical Officer at Forest and ExecutiveVice President of the Forest Research Institute. He joined Forest in 1998as Executive Director of Clinical Research following nine years atSmithKline Beecham and was named Vice President of Clinical Development andClinical Affairs in 1999. He oversaw all clinical development programs atForest including the development of Lexapro®, an SSRI antidepressant,Namenda®, an NMDA receptor antagonist for the treatment of moderate tosevere Alzheimer's Disease and Combunox(TM), an opioid and NSAIDcombination indicated for the short-term management of acute, moderate tosevere pain.

Dr. Gergel received his MD from The Royal Free Medical School of TheUniversity of London and an MBA from the Wharton School.

Dave Holveck, President and Chief Executive Officer of EndoPharmaceuticals, commented: "I am pleased to welcome Ivan to the Endo team.Ivan has extensive experience as both a clinician and researcher.Additionally, throughout his career at Forest, Ivan demonstrated leadershipand expertise. These are all qualities that will serve Endo well."

About Endo

Endo Pharmaceuticals Holdings Inc. is a specialty pharmaceutical companywith market leadership in pain management. Through its wholly owned EndoPharmaceuticals Inc. subsidiary, the company is engaged in the research,development, sale and marketing of branded and generic prescriptionpharmaceuticals used primarily to treat and manage pain. More information,including this and past press releases of Endo Pharmaceuticals HoldingsInc., is available at www.endo.com.

Forward-Looking Statements

This press release contains information that includes or is based on"forward-looking statements" within the meaning of Section 27A of theSecurities Act of 1933, as amended, or the Securities Act, and Section 21Eof the Securities Exchange Act of 1934, as amended, or the Exchange Act.These statements, including estimates of future net sales, future expenses,future net income and future earnings per share, are subject to risks anduncertainties. Forward-looking statements include the informationconcerning the company's possible or assumed results of operations. Also,statements including words such as "believes," "expects," "anticipates,""intends," "estimates," "plan," "will," "may" or similar expressions areforward-looking statements. Endo has based these forward-looking statementson its current expectations and projections about the growth of itsbusiness, its financial performance and the development of its industry.Because these statements reflect Endo's current views concerning futureevents, these forward-looking statements involve risks and uncertainties.Investors should note that many factors could affect Endo's futurefinancial results and could cause its actual results to differ materiallyfrom those expressed in forward-looking statements contained in this pressrelease. Important factors that could cause its actual results to differmaterially from the expectations reflected in the forward-lookingstatements in this press release include, but are not limited to: itsability to successfully develop, commercialize and market new products;timing and results of pre-clinical or clinical trials on new products; itsability to obtain regulatory approval of any of its pipeline products;competition for the business of its branded and generic products, and inconnection with its acquisition of rights to intellectual property assets;market acceptance of its future products; government regulation of thepharmaceutical industry; its dependence on a small number of products; itsdependence on outside manufacturers for the manufacture of its products;its dependence on third parties to supply raw materials and to provideservices for certain core aspects of its business; new regulatory action orlawsuits relating to its use of narcotics in most of its core products; itsexposure to product liability claims and product recalls and thepossibility that the company may not be able to adequately insure itself;its ability to protect its proprietary technology; the successful effortsof manufacturers of branded pharmaceuticals to use litigation andlegislative and regulatory efforts to limit the use of generics and certainother products; its ability to successfully implement its acquisition andin-licensing strategy; regulatory or other limits on the availability ofcontrolled substances that constitute the active ingredients of some of itsproducts and products in development; the availability of third-partyreimbursement for its products; the outcome of any pending or futurelitigation or claims by the government; its dependence on sales to alimited number of large pharmacy chains and wholesale drug distributors fora large portion of its total net sales; significant litigation expenses todefend or assert patent infringement claims; any interruption or failure byits suppliers, distributors and collaboration partners to meet theirobligations pursuant to various agreements with Endo; a determination by aregulatory agency that Endo is engaging in inappropriate sales or marketingactivities, including promoting the "off-label" use of its products;existing suppliers become unavailable or lose their regulatory status as anapproved source, causing an inability to obtain required components, rawmaterials or products on a timely basis or at commercially reasonableprices; the loss of branded product exclusivity periods and relatedintellectual property; and its exposure to securities that are subject tomarket risk. The company does not undertake any obligation to update itsforward-looking statements after the date of this press release for anyreason, even if new information becomes available or other events occur inthe future. You are advised, however, to consult any further disclosures wemake on related subjects in our 10-K, 10-Q and 8-K reports to theSecurities and Exchange Commission (or SEC). Also note that Endo providesthe preceding cautionary discussion of risks, uncertainties and possiblyinaccurate assumptions relevant to its business. These are factors that,individually or in the aggregate, the company believes could cause itsactual results to differ materially from expected and historical results.Endo notes these factors for investors as permitted by the PrivateSecurities Litigation Reform Act of 1995. You should understand that it isnot possible to predict or identify all such factors. Consequently, youshould not consider the preceding to be a complete discussion of allpotential risks or uncertainties.

Add to Digg Bookmark with del.icio.us Add to Newsvine